Antonio Llombart (Antonio Llombart-Cussac)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 17

Top Topics

Early Breast Cancer

Positron Emission Tomography

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

European journal of nuclear medicine and molecular imaging

This page only lists publications with an associated author ORCID identifier.

Publications

Antonio Llombart, Aleix Prat, José Manuel Pérez-García, José Mateos, Tomás Pascual, Santiago Escrivà-de-Romani, Agostina Stradella, Manuel Ruiz-Borrego, Begoña Bermejo de Las Heras, Marleen Keyaerts, Patricia Galvan, Fara Brasó-Maristany, Juan José García-Mosquera, Thomas Guiot, María Gion, Miguel Sampayo-Cordero, Serena Di Cosimo, Jhudit Pérez-Escuredo, Manuel Atienza de Frutos, Javier Cortés, Geraldine Gebhart
Clinicopathological and molecular predictors of [ 18 F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. European journal of nuclear medicine and molecular imaging 51 (9) (2024)
Antonio Llombart, José Pérez-García, Fara Brasó-Maristany, Laia Paré, Guillermo Villacampa, Maria Gion, Peter Schmid, Marco Colleoni, Manuel Ruiz Borrego, Patricia Galván, Joel S Parker, Wesley Buckingham, Charles M Perou, Patricia Villagrasa, Jose Antonio Guerrero, Miguel Sampayo, Mario Mancino, Aleix Prat, Javier Cortes
HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Antonio Llombart, Aleix Prat, José Manuel Pérez-García, José Mateos, Tomás Pascual, Santiago Escrivà-de-Romani, Agostina Stradella, Manuel Ruiz-Borrego, Begoña Bermejo de Las Heras, Marleen Keyaerts, Patricia Galvan, Fara Brasó-Maristany, Juan José García-Mosquera, Thomas Guiot, María Gion, Miguel Sampayo-Cordero, Serena Di Cosimo, Jhudit Pérez-Escuredo, Manuel Atienza de Frutos, Javier Cortés, Geraldine Gebhart
Clinicopathological and molecular predictors of [ 18 F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. European journal of nuclear medicine and molecular imaging (2024)
Juan Carlos Andreu-Ballester, Lorena Galindo-Regal, Carmen Cuéllar Del Hoyo, Francisca López-Chuliá, Carlos García-Ballesteros, María Leonor Fernández-Murga, Antonio Llombart, María Victoria Domínguez-Márquez
A Low Number of Baselines γδ T Cells Increases the Risk of SARS-CoV-2 Post-Vaccination Infection. Vaccines 12 (5) (2024)
Antonio Llombart, Aleix Prat, José Manuel Pérez-García, José Mateos, Tomás Pascual, Santiago Escrivà-de-Romani, Agostina Stradella, Manuel Ruiz-Borrego, Begoña Bermejo de Las Heras, Marleen Keyaerts, Patricia Galvan, Fara Brasó-Maristany, Juan José García-Mosquera, Thomas Guiot, María Gion, Miguel Sampayo-Cordero, Serena Di Cosimo, Jhudit Pérez-Escuredo, Manuel Atienza de Frutos, Javier Cortés, Geraldine Gebhart
Clinicopathological and molecular predictors of [ 18 F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. European journal of nuclear medicine and molecular imaging 51 (9) (2024)
Miguel Quintela-Fandino, Begoña Bermejo, Esther Zamora Adelantado, Fernando Moreno Antón, José Angel García-Saenz, Sonia Pernas, Noelia Martínez Jáñez, Desirée Jiménez, Encarna Adrover, R Andrés Conejero, Silvana Mourón, Maria Jose Bueno, Luis Manso Sanchez, Gemma Viñas, Emilio Alba, Antonio Llombart, Javier Cortes, Cristina Tebar, Denise J Roe, Adam Grant, Adam W Watson, Ramón Colomer, Ghassan Mouneimne
High mechanical conditioning by tumor extracellular matrix stiffness is a predictive biomarker for anti-fibrotic therapy in HER2-negative breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Antonio Llombart, Aleix Prat, José Manuel Pérez-García, José Mateos, Tomás Pascual, Santiago Escrivà-de-Romani, Agostina Stradella, Manuel Ruiz-Borrego, Begoña Bermejo de Las Heras, Marleen Keyaerts, Patricia Galvan, Fara Brasó-Maristany, Juan José García-Mosquera, Thomas Guiot, María Gion, Miguel Sampayo-Cordero, Serena Di Cosimo, Jhudit Pérez-Escuredo, Manuel Atienza de Frutos, Javier Cortés, Geraldine Gebhart
Clinicopathological and molecular predictors of [ 18 F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. European journal of nuclear medicine and molecular imaging 51 (9) (2024)
Antonio Llombart, Aleix Prat, José Manuel Pérez-García, José Mateos, Tomás Pascual, Santiago Escrivà-de-Romani, Agostina Stradella, Manuel Ruiz-Borrego, Begoña Bermejo de Las Heras, Marleen Keyaerts, Patricia Galvan, Fara Brasó-Maristany, Juan José García-Mosquera, Thomas Guiot, María Gion, Miguel Sampayo-Cordero, Serena Di Cosimo, Jhudit Pérez-Escuredo, Manuel Atienza de Frutos, Javier Cortés, Geraldine Gebhart
Clinicopathological and molecular predictors of [ 18 F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. European journal of nuclear medicine and molecular imaging 51 (9) (2024)
Juan Carlos Andreu-Ballester, Lorena Galindo-Regal, Carmen Cuéllar Del Hoyo, Francisca López-Chuliá, Carlos García-Ballesteros, María Leonor Fernández-Murga, Antonio Llombart, María Victoria Domínguez-Márquez
A Low Number of Baselines γδ T Cells Increases the Risk of SARS-CoV-2 Post-Vaccination Infection. Vaccines 12 (5) (2024)
María Leonor Fernández-Murga, Fernando Gil-Ortiz, Lucía Serrano-García, Antonio Llombart
A New Paradigm in the Relationship between Gut Microbiota and Breast Cancer: β-glucuronidase Enzyme Identified as Potential Therapeutic Target. Pathogens (Basel, Switzerland) 12 (9) (2023)
Antonio Llombart, Antonio Anton-Torres, Beatriz Rojas, Raquel Andrés, Noelia Martinez, César A Rodríguez, Sara Marin, Teresa Puértolas, Alejandro Falcón González, María Leonor Fernández-Murga, Carlos Hagen, Manuel Ruiz-Borrego
Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study. Cancers 15 (5) (2023)
Antonio Llombart, Antonio Anton-Torres, Beatriz Rojas, Raquel Andrés, Noelia Martinez, César A Rodríguez, Sara Marin, Teresa Puértolas, Alejandro Falcón González, María Leonor Fernández-Murga, Carlos Hagen, Manuel Ruiz-Borrego
Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study. Cancers 15 (5) (2023)
Matthew P Goetz, Erika Paige Hamilton, Mario Campone, Sara Alsterlind Hurvitz, Javier Cortes, Stephen R D Johnston, Antonio Llombart, Peter A Kaufman, Masakazu Toi, Guy Jerusalem, Hillary Graham, Hong Wang, Valerie M Jansen, Lacey M Litchfield, Miguel Martin
Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Joan Albanell, José Manuel Peréz-García, Juan Miguel Gil-Gil, Curigliano Giuseppe, Manuel Ruiz Borrego, Laura Comerma, Joan Gibert, Meritxell Bellet-Ezquerra, Begoña Bermejo, Lourdes Calvo Martinez, Juan R De la Haba-Rodríguez, Enrique Espinosa, Alessandro Marco Marco Minisini, Vanesa Quiroga, Ana Santaballa Bertran, Leonardo Mina, Beatriz Bellosillo, Federico Rojo, Silvia Menéndez, Miguel Sampayo, Ramona Mihaela Popa, Andrea Malfettone, Javier Cortes, Antonio Llombart
Palbociclib Rechallenge for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Sara M Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart, Hatem H Soliman, Hong Wang, Sameera Wijayawardana, Valerie M Jansen, Lacey M Litchfield, George W Sledge
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (8) (2022)
Tomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, Maria Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarnieri, Javier Cortes, Patricia Villagrasa, Núria Chic, María Jesús Vidal Losada, Barbara Adamo, Montserrat Muñoz, Gaia Griguolo, Antonio Llombart, PierFranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Paré, Patricia Galvan, Lisa Anne Carey, Charles M Perou, Aleix Prat
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (11) (2021)
Patrick Neven, Stephen R D Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A Kaufman, Han Koh, Eva-Maria Grischke, PierFranco Conte, Yi Lu, Nadine Haddad, Karla C Hurt, Antonio Llombart, George W Sledge
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (21) (2021)